Early-Phase Clinical Trials for Blood Cell Therapies (R01)

The summary for the Early-Phase Clinical Trials for Blood Cell Therapies (R01) grant is detailed below. This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact. If any section is incomplete, please visit the website for the National Institutes of Health, which is the U.S. government agency offering this grant.
Early-Phase Clinical Trials for Blood Cell Therapies (R01): This FOA issued by the National Heart, Lung, and Blood Institute, National Institutes of Health, encourages Research Project Grant (R01) applications from institutions and organizations for the purpose of supporting early-phase clinical trials i.e., first-in-human, phase I, or phase II trialsto evaluate innovative and novel cell therapies to treat blood diseases and/or to improve the outcome of hematopoietic stem cell transplantations.
Federal Grant Title: Early-Phase Clinical Trials for Blood Cell Therapies (R01)
Federal Agency Name: National Institutes of Health
Grant Categories: Health
Type of Opportunity: Discretionary
Funding Opportunity Number: PAR-11-204
Type of Funding: Grant
CFDA Numbers: 93.839
CFDA Descriptions: Blood Diseases and Resources Research
Current Application Deadline: Jan 07, 2013
Original Application Deadline: Jan 07, 2013
Posted Date: Apr 20, 2011
Creation Date: Apr 20, 2011
Archive Date: Feb 07, 2013
Total Program Funding:
Maximum Federal Grant Award:
Minimum Federal Grant Award:
Expected Number of Awards:
Cost Sharing or Matching: No
Applicants Eligible for this Grant
State governments - County governments - City or township governments - Special district governments - Independent school districts - Public and State controlled institutions of higher education - Native American tribal governments (Federally recognized) - Public housing authorities/Indian housing authorities - Native American tribal organizations (other than Federally recognized tribal governments) - Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education - Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education - Private institutions of higher education - For profit organizations other than small businesses - Small businesses - Others (see text field entitled "Additional Information on Eligibility" for clarification)
Additional Information on Eligibility
Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Organizations) are not eligible to apply. Foreign (non-U.S.) components of U.S. Organizations are not allowed.
Link to Full Grant Announcement
http://grants.nih.gov/grants/guide/pa-files/par-11-204.html
Grant Announcement Contact
NIH OER WebmasterFBOWebmaster@OD.NIH.GOV
If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster [FBOWebmaster@OD.NIH.GOV]
Similar Government Grants
Stem Cell-Derived Blood Products for Therapeutic Use: Technology Improvement (R43/R44)
Stem Cell-Derived Blood Products for Therapeutic Use: Technology Improvement (R41)
Stem Cell-Derived Blood Products for Therapeutic Use (R01)
Vascular Dysfunction in the Pathogenesis of Severe Malaria (R01)
Enriching the Hematology Research Workforce through Short-term Educational Experiences in ...
Improved Therapy for Hemophilia and Hereditary Bleeding Disorders
Clinical Hematology Research Career Development Program (K12)
Molecular Mechanisms Underlying Diamond-Blackfan Anemia and Other Congenital Bone Marrow F...
More Grants from the National Institutes of Health
Lab to Marketplace: Tools for Biomedical and Behavioral Research (R43/R44)
Novel Assays for Screening the Effects of Chemical Toxicants on Cell Differentiation (R43/...
Novel Assays for Screening the Effects of Chemical Toxicants on Cell Differentiation (R41)
Cancer Detection, Diagnosis, and Treatment Technologies for Global Health (UH2/UH3)
Systems Science and Health in the Behavioral and Social Sciences (R01)

FederalGrants.com is not endorsed by, or affiliated with, any government agency. Copyright ©2014 FederalGrants.com